Gilead Sciences

Triple combination regimen to be investigated in new Phase 2b study in NASH patients with cirrhosis

Collaboration to focus on oral and injectable formulations of Lenacapavir and Islatravir

One big-ticket deal contributes 70.5 per cent of the total deal value in December 2020

Under the new arrangement, Galapagos will assume sole responsibility in Europe for filgotinib in RA, Gilead to receive royalties…

Gilead to acquire Hepcludex, a first-in-class entry inhibitor, for treatment of chronic hepatitis delta virus (HDV), after closing…

Main reasons for disruption in India include travel constraints, fear of getting COVID-19

The FDA granted the drug accelerated approval for its use in metastatic triple-negative breast cancer (mTNBC) patients who had…

The drug will be produced at its sterile drug product manufacturing plant in Hyderabad which is WHO GMP certified

The deal, which will expand Gilead’s oncology portfolio, might get announced tomorrow if not sooner, inform reports

Jounce will lead the development of JTX-1811 through IND clearance, and thereafter, Gilead will have the sole right to develop…